Cardiology
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology
Genetics
Geriatrics/Aging
Hematology/Oncology
Immunology/Allergy
Infectious Disease
Nephrology
Neurology/Neurosurgery
Obstetrics/Gynecology
Pediatrics
Psychiatry
Public Health, Policy, and Training
Pulmonary
Rheumatology
Surgery

Nejm News Une Mise à Jour The New England Journal of Medicine by Specialties

 


The New England Journal of Medicine: Search Results in Hematology\Oncology
The New England Journal of Medicine (NEJM) RSS feed -- Search Results in Hematology\Oncology. NEJM (http://www.nejm.org) is a weekly general medical journal that publishes new medical research findings, review articles, and editorial opinion on a wide variety of topics of importance to biomedical science and clinical practice.

Advantages of a Truly Open-Access Data-Sharing Model
01/01/70 - Multi-institutional randomized clinical trials have been a feature of oncology research in the United States since the 1950s. Since that time, cancer-treatment trials have been continuously funded by the National Cancer Institute (NCI) through a program that has evolved to become the National…

ST2 and Endothelial Injury as a Link between GVHD and Microangiopathy
01/01/70 - To the Editor: Vander Lugt et al. (Aug. 8, 2013, issue) report an association between elevated levels of ST2 protein, a marker of endothelial injury, at the time of diagnosis of graft-versus-host disease (GVHD) and resistance to glucocorticoid therapy among the recipients of hematopoietic stem-cell…

Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
01/01/70 - Venous thromboembolism, which includes deep-vein thrombosis and pulmonary embolism, is the third most common cause of vascular death after myocardial infarction and stroke. The mainstay of treatment is anticoagulation, and in patients without active cancer, guidelines suggest the use of direct oral…

Reduced-Intensity Rivaroxaban for the Prevention of Recurrent Venous Thromboembolism
01/01/70 - Warfarin and direct oral anticoagulant agents prevent recurrent venous thromboembolism. When a first episode of venous thromboembolism occurs in association with a transient risk factor (e.g. surgery), treatment can be stopped after 3 months. With persistent and strong risk factors, such as cancer,…

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
01/01/70 - Urothelial cancer is highly lethal in the metastatic state. Platinum-based combination chemotherapy remains the standard first-line treatment for metastatic disease. Carboplatin-based combinations are associated with a median overall survival of 9 months, and cisplatin-based combinations with a…

Clarifying Stem-Cell Therapy?s Benefits and Risks
01/01/70 - The current excitement over the potential for stem-cell therapy to improve patient outcomes or even cure diseases is understandable. We at the Food and Drug Administration (FDA) share this excitement. However, to ensure that this emerging field fulfills its promise to patients, we must first…

Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma
01/01/70 - Glioblastoma is a fatal illness that is associated with a median survival of less than 2 years. Population studies of glioblastoma have shown that survival declines with increasing age, and the incidence of glioblastoma is increasing, especially among the elderly. Older patients have been…

Lessons from Oregon in Embracing Complexity in End-of-Life Care
01/01/70 - Under the incentives of fee-for-service Medicare, the utilization trends among persons with chronic progressive medical illness include more care in the intensive care unit (ICU), more hospitalizations, and often late or no referrals to hospice care (Figure 1). These utilization patterns are…

PD-1 and PD-L1 Inhibitors as Salvage Therapy for Urothelial Carcinoma
01/01/70 - For more than two decades, the only therapy that was proven to extend overall survival among patients with advanced urothelial carcinoma was cisplatin-based combination chemotherapy. First-line cisplatin-based chemotherapy yields a median overall survival of 14 to 15 months, coupled with 5-year…

Plasmacytomas and Plasma-Cell Leukemia
01/01/70 - Figure 1.

Copyright © 2004/2011 Health.Cat

Annuaire de Sante | S'inscrire au MedSante  | Dictionnaire medicale  Forumed des médecins